Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-01-23
2009-02-10
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S515000
Reexamination Certificate
active
07488748
ABSTRACT:
This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
REFERENCES:
patent: 3176019 (1965-03-01), Campbell et al.
patent: 4595690 (1986-06-01), Clark et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5948792 (1999-09-01), Tsuchiya et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6174900 (2001-01-01), Okada et al.
patent: 6559162 (2003-05-01), Bjorsne et al.
patent: 0 325 571 (1989-07-01), None
patent: 0 383 256 (1990-08-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 751 127 (1997-01-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 823 423 (1998-02-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 940540 (1963-10-01), None
patent: 92921/1994 (1994-04-01), None
patent: 135958/1994 (1994-05-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 93/16018 (1993-08-01), None
patent: WO 93/16048 (1993-08-01), None
patent: WO 95/06635 (1995-03-01), None
patent: WO 96/33973 (1996-10-01), None
patent: WO 97/45414 (1997-12-01), None
patent: WO 98/05641 (1998-02-01), None
patent: WO 98/29402 (1998-07-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Wess et al. Life Sciences 2003, 72, 2047-2054.
O'Neill, M. Drug Discovery Today Oct. 2005, 10(20), 1338.
Michel et al. Naunyn-Schmiedeberg's Arch Pharmacol 2006, 374, 79-85.
Latifpour et al. The Journal of Pharmacology and Experimental Therapeutics 1989, 249(1), 81-88.
Carrier et al. The Journal of Pharmacology and Experimental Therapeutics 1987, 242(2), 531-535.
Ahren et al. Diabetologia 1996, 39, 383-390.
Abrams et al. British Journal of Pharmacology 2006, 148, 565-578.
Birdsall et al., “Muscarinic receptors: it's a knockout”,Trends in Pharmacological Sciences, 22(5):215-219 (2001).
Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder”,Urology, 55(Suppl. 5A):33-46 (2000).
Eglen et al., “Theraputic opportunities from muscarinic receptor research”,Trends in Pharmacological Sciences, 22(8):409-414 (2001).
Felder et al., “Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System”,Journal of Medicinal Chemistry, 43(23):4333-4353 (2000).
Steers, Barrot, Wein, “Voiding dysfunction: diagnosis classification and management”, In:Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996).
Kadin and Cannon, “Esters ofN-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II”,Journal of Organic Chemistry, 27:240-245 (1962).
Lee et al, “Evaluation of Stereoisomers of 4-Fluoroalkyl Analogues of 3-Quinuclidinyl Benzilate in In Vivo Competition Studies for the M1, M2 and M3 Muscarinic Receptor Subtypes in Brain”,Nuclear Medicine and Biology, 22(6):773-781 (1995) XP004051742, ISSN: 0969-8051.
Steers, “The future direction of neuro-urology drug research”,Current Opinion in CPNS Investigational Drugs, 2(3):268-282.
Cheng and Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”,Biochemical Pharmacology, 22:3099-3108 (1973).
Eglen et al., “Muscarinic receptor ligands and their theraputic potential”,Current Opinion in Chemical Biology, 3:426-432 (1999).
Shacklett and Smith, “The Preparation of Substituted Benzilic Acids”,Journal of the American Chemical Society, 75:2654-2657 (1953).
Sagara et al., “Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes”,Journal of Medicinal Chemistry, 45:984-987 (2002).
Moriya et al., “Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland”,Life Sciences, 64(25):2351-2358 (1999).
Broadley and Kelly, “Muscarinic Receptor Agonists and Antagonists”,Molecules, 6:142-193 (2001).
Kubo et al., “Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor”,Nature, 323(2):411-416 (1986).
Horning, E.C., 1955,Organic Syntheses, Collective Vol. 3. Hoboken, NJ: John Wiley and Sons, p. 220.
de Groat and Yoshimura, “Pharmacology of the Lower Urinary Tract”,Annual Review of Pharmacology and Toxicology, 41:691-721 (2001).
Bonner et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237:527-531 (1987).
Biel et al., “Central Stimulants. II. Cholinergic Blocking Agents1”,Journal of Organic Chemistry, 26:4096-4103 (1961).
Taniguchi et al, “Agents for the Treatment of Overactive Detrusor. VI1α). Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines inN-Substituents”,Chemical and Pharmaceutical Bulletin, 42(1):74-84 (1994).
Gupta Jang Bahadur
Kumar Naresh
Mehta Anita
Silamkoti Arundutt V.
Deshmukh Esq. Jayadeep R.
Heibel Esq. George E.
Nolan Jason M
Ranbaxy Laboratories Limited
Saeed Kamal A
LandOfFree
3,6-Disubstituted azabicyclo hexane derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,6-Disubstituted azabicyclo hexane derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,6-Disubstituted azabicyclo hexane derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4091005